Results 151 to 160 of about 149,243 (305)

Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents

Alimentary Pharmacology &Therapeutics, EarlyView.
HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi, Makoto Saito, Kazuya Okushin, Toshiyuki Kishida, Akira Kado, Kyoji Moriya, Kazuhiko Koike, Takeya Tsutsumi, Hiroshi Yotsuyanagi   +8 more
wiley   +1 more source

Socioeconomic Inequalities in Receipt of Curative‐Intent Treatment and Survival After Surveillance‐Detected Hepatocellular Carcinoma: A Nationwide Cohort Study

Alimentary Pharmacology &Therapeutics, EarlyView.
Socioeconomic inequalities in receipt of curative‐intent treatment and survival persist among individuals with surveillance‐detected HCC within a universal healthcare system. These findings suggest that surveillance alone is insufficient to ensure equitable outcomes and highlight the need for strategies addressing social determinants across the care ...
Hannes Hagström, Jeffrey V. Lazarus, Malin Sternby Eilard, Adam Bergman, Magnus Rizell, Per Sandström, Juan Vaz   +6 more
wiley   +1 more source

Clinical Burden of Symptomatic HEV‐3 Infection in Southern Spain

Alimentary Pharmacology &Therapeutics, EarlyView.
Clinical burden of symptomatic HEV‐3 infection in southern Spain. Between 2022 and 2025, 1124 patients with acute hepatitis, defined as ALT ≥ 3 times the upper limit of normal and negative screening for HAV, HBV, HCV, EBV and CMV, were evaluated in Andalusia.
María Casares‐Jimenez, Claudia Ferreira‐Tata, Isabel Viciana, Carolina Freyre‐Carrillo, Pedro Lopez‐Lopez, Ana Belen Perez, Berta Becerril‐Carral, Ana Fuentes, Juan Macías, Lucia Rios‐Muñoz, Francisco Franco‐Alvarez de Luna, María Teresa Cabezas‐Fernandez, Diana Corona‐Mata, Antonio Rivero‐Juarez, Antonio Rivero   +14 more
wiley   +1 more source

Harnessing Nature's Gifts: Salix nigra and Its Potential for Combating Hepatitis C Virus (HCV). [PDF]

ACS Omega, 2023
Bibi S, Nisar M, Rafique S, Waqas M, Zahoor M, Idrees M, Nazir N, Ihsan M, Salmen SH, Alharbi SA, Khan A, Al-Harrasi A.   +11 more
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Identification of the Genotypes Circulating in the Ecuadorian Population Infected with the Hepatitis C Virus (HCV). [PDF]

Risk Manag Healthc Policy, 2023
Moncayo M, Teran E, Reyes J, Yerovi G, Robalino M, Aguilar AC, Garzon-Chavez D.   +6 more
europepmc   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Interventions for dialysis patients with hepatitis C virus (HCV) infection. [PDF]

Cochrane Database Syst Rev, 2023
Prabhu AR, Rao IR, Nagaraju SP, Rajwar E, Venkatesh BT, Nair N S, Pai G, Reddy NP, Suvarna D.   +8 more
europepmc   +1 more source

Targeting Egfr‐Mediated Cell Proliferation and Lipid Metabolism Separation Effectively Accelerate Liver Regeneration

Cell Proliferation, EarlyView.
AREG coordinates cell proliferation and lipid metabolism reprogramming during liver regeneration and targeting lipid metabolism can promote liver regeneration. ABSTRACT Hepatocyte proliferation restores liver mass after partial hepatectomy (PHx), but the metabolic cost of this process remains unclear.
Yuelei Hu, Shifei Song, Ruilin Wang, Ni An, Jinmei Diao, Yuguo Chen, Juan Liu, Guoyue Lv   +7 more
wiley   +1 more source

The Seroprevalence of Hepatitis C Virus (HCV) in Hemodialysis Patients in Oman: A National Cross-Sectional Study. [PDF]

J Epidemiol Glob Health, 2023
Al Shukri I, Al Wahaibi A, Al Kindi H, Al-Maimani Y, Al Maani A, Alqayoudhi A, Methew MC, Pradeesh J, Al Abrawi R, Debs A, Mansoor N, AlRahbi A, Al Balushi W, Alharrasi M, Al Mamari B, Soliman MF, Alsenaidi A, Al Alawi M, Al Ismaili O, Al-Abri S, Al-Jardani A.   +20 more
europepmc   +1 more source